Tissue-resident memory T cells in immune-related adverse events: friend or foe?

Abstract

Many cancer patients experience toxicity during checkpoint blockade immunotherapy, which often leads to treatment discontinuation. To this end, understanding the mechanisms mediating immune-related adverse events (irAE) should ultimately enable improvement in clinical outcomes. Recent work has revealed that tissue-resident memory T (TRM) cells are locally expanded in irAE-dermatitis and -colitis.

Keywords

• immune-related adverse events
• irAE
• tissue-resident memory T cells
• checkpoint blockade